Viamet Pharmaceuticals Announces Agreement with National Institute of Allergy And Infectious Diseases (NIAID) to Advance Novel Class of Broad-Spectrum Antifungal Compounds

Published: Jun 19, 2012

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals, Inc., a world leader in the development of “best-in-class” products targeting metalloenzymes, announced today that it has entered into a Non-Clinical Evaluation Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Under this agreement, Viamet will utilize NIAID’s preclinical services program to further develop a novel class of broad-spectrum antifungal agents conceived by Viamet.

Back to news